Get the Stockscreener App
21.51
1.18%
0.25
Castle Biosciences Inc stock is traded at $21.51, with a volume of 454.03K.
It is up +1.18% in the last 24 hours and up +7.39% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
See More
Previous Close:
$21.26
Open:
$21.14
24h Volume:
454.03K
Relative Volume:
1.12
Market Cap:
$573.73M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-10.00
EPS:
-2.15
Net Cash Flow:
$-19.25M
1W Performance:
+11.45%
1M Performance:
+7.39%
6M Performance:
-34.94%
1Y Performance:
+14.17%
1-Day Range:
$21.13
$21.81
1-Week Range:
$19.12
$21.81
52-Week Range:
$16.96
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Compare CSTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
21.51 | 573.73M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)? - simplywall.st
Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern - Seeking Alpha
Castle Biosciences to Release First Quarter 2025 Financial Resul - GuruFocus
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025 - GlobeNewswire
Castle Biosciences Sets Q1 Earnings Date: Key Financial Updates Coming May 5 - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by Franklin Resources Inc. - Defense World
28,903 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Acquired by Arrowstreet Capital Limited Partnership - Defense World
Vanguard Group Inc. Has $48.84 Million Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Corebridge Financial Inc. Has $343,000 Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences CEO Derek Maetzold sells $113,931 in stock By Investing.com - Investing.com Canada
KLP Kapitalforvaltning AS Buys New Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
SEC Form DEF 14A filed by Castle Biosciences Inc. - Quantisnow
American Century Companies Inc. Has $1.84 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences backs esophageal cancer awareness By Investing.com - Investing.com South Africa
Castle Biosciences backs esophageal cancer awareness - Investing.com
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships - GlobeNewswire
Game-Changing Esophageal Cancer Detection: Castle Bio Partners With Top Medical Networks - Stock Titan
Sei Investments Co. Boosts Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year - GlobeNewswire
Castle Biosciences Ranks #30 Among Best U.S. Workplaces: 85% Employee Engagement Score - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of “Buy” by Brokerages - Defense World
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test - The Manila Times
Publication of Data from Prospective, Multicenter Study - GlobeNewswire
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test - Yahoo Finance
Breakthrough Melanoma Test Shows 100% Accuracy in Avoiding Unnecessary Cancer Surgeries - Stock Titan
Are Castle Biosciences, Inc.'s (NASDAQ:CSTL) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Yahoo Finance
Teacher Retirement System of Texas Makes New $253,000 Investment in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma - The Manila Times
Castle Biosciences to Present New Data at EADO Supporting - GlobeNewswire
Breakthrough Melanoma Test Data Reveals Critical Survival Predictions for High-Risk Patients - Stock Titan
Castle Biosciences CEO Derek Maetzold sells $114,573 in stock - Investing.com Australia
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups - The Manila Times
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five - GlobeNewswire
Breakthrough Study: Top-Ranked Cancer Test Doubles Accuracy in Predicting Metastatic Risk - Stock Titan
Castle Biosciences CEO Derek Maetzold sells $114,573 in stock By Investing.com - Investing.com UK
Castle Biosciences, Inc. (NASDAQ:CSTL) Position Trimmed by Charles Schwab Investment Management Inc. - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by Bank of New York Mellon Corp - Defense World
Bank of New York Mellon Corp Has $2.25 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - The AM Reporter
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Beyond the Lab: Artificial Intelligence - Drug Target Review
US Bancorp DE Sells 3,413 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Assetmark Inc. Has $118,000 Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Castle Biosciences CEO Derek Maetzold sells $585,673 in stock - Investing.com India
Castle Biosciences CEO Derek Maetzold sells $585,673 in stock By Investing.com - Investing.com UK
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio - Business Wire
Castle Biosciences Inc to Host Earnings Call - ACCESS Newswire
Solid Earnings Reflect Castle Biosciences' (NASDAQ:CSTL) Strength As A Business - Yahoo Finance
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Rhumbline Advisers - Defense World
What is Leerink Partnrs’ Forecast for CSTL Q1 Earnings? - Armenian Reporter
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):